Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Cona
Clinical trial register · Italy

Clinical Trials in Cona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 73 Roma 52 Rozzano 26 Florence 24 Ancona 24
Narrow the registerReset
Recruitment status
Phase
Site location
Milan73 Roma52 Rozzano26 Florence24 Ancona24
All 66 locations
Target enrolment
to

Trials with a site in Cona

14 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Ancona, Bergamo, Bologna, Brescia, Cona, Florence, Pozzilli, Milan
2026-05-11
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Ancona, Cona, Milan, Rozzano
2026-03-09
Recruiting
Novartis Pharmaceuticals
Observational
250
Ancona, Bari, Brescia, Cona, Florence, Genova, Lecce, Messina
2025-12-17
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals
Phase 1/2
123
Cona, Milan, Naples
2025-12-05
Recruiting
Novartis Pharmaceuticals
Observational
300
Alessandria, Asti, Bergamo, Brescia, Catania, Meldola, Cona, Foggia
2025-07-30
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals
Phase 3
240
Cona, Genova, Milan, Rozzano, Pisa, Roma
2025-05-30
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Ancona, Cona, Pisa
2025-05-16
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Ancona, Brescia, Catania, Cona, Florence, Rozzano, Modena, Pisa
2025-01-31
Active, closed
Novartis Pharmaceuticals
Observational
379
Ancona, L’Aquila, Bari, Bergamo, Chieti, Catania, Catanzaro, Cona
2024-07-30
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Cona, Pisa, Roma, Torino
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Brescia, Cona, Genova, Milan, Rozzano, Pisa, Roma, Negrar
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Ancona, Bergamo, Bologna, Brescia, Caserta, Cona, Pozzilli, Milan
2024-03-07
Active, closed
Novartis Pharmaceuticals
Phase 3
288
Ancona, Cona, Padova, Pisa, Roma, Torino
2023-04-21
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Bologna, Brescia, Cona, Florence, Grosseto, Pozzilli, Milan, Rozzano
2021-11-23
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-italy/city/cona

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies with a site in Cona that also match the filters currently applied.

How many clinical trials are recruiting in Cona?

10 of the 14 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cona), 14 studies
PhaseStudiesRecruitingShare
Phase 37450%
Observational3221.4%
Phase 23321.4%
Phase 1/2117.1%

Most active sponsors

Lead sponsors with the most studies (Cona)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals1410
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.